Who Owns Panadol?
Panadol is owned by Haleon, a British multinational consumer healthcare company spun off from GSK in 2022. Panadol operates as Haleon's flagship pain relief brand and is manufactured in multiple facilities worldwide.
Parent Company
Haleon plc
Founded
1955
Status
Publicly Traded
Headquarters
Weybridge, Surrey, United Kingdom
Who Owns Panadol?
- Parent Company: Haleon plc
- Ownership Type: Wholly owned
- Company Type: Publicly Traded
- Stock Ticker: LSE: HLN
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Panadol | Haleon plc | Wholly owned |
History of Panadol
- Founded: 1955
- Founders: Frederick Stearns
Panadol was first introduced in 1955 by Frederick Stearns, an American pharmaceutical entrepreneur. This founding vision demonstrated exceptional insight into the growing demand for healthcare pharmaceuticals solutions while establishing a distinctive approach that would define the healthcare pharmaceuticals category for generations. The medication was developed as a paracetamol-based pain reliever that could be sold without prescription in pharmacies and other retail outlets. This strategic positioning demonstrated Panadol's exceptional ability to create differentiated healthcare pharmaceuticals solutions while maintaining consistent brand positioning and quality standards that would define the brand for decades.
Throughout the 1960s and 1970s, Panadol expanded globally, becoming one of the world's most recognized pain relief brands. This period of excellence demonstrated Panadol's exceptional ability to scale operations while maintaining consistent brand positioning and quality standards across multiple healthcare pharmaceuticals segments. The medication was acquired by various pharmaceutical companies before becoming part of the Beecham Group and later GSK portfolio. This strategic diversification demonstrated Panadol's exceptional ability to serve multiple consumer segments while maintaining its core brand identity and market leadership in the healthcare pharmaceuticals industry.
The 1980s and 1990s saw Panadol expand its product range with various formulations including Panadol Extra, Panadol Advance, and other specialized versions. This continued evolution demonstrated Panadol's exceptional ability to maintain market relevance while adapting to changing healthcare pharmaceuticals requirements and technological advancements. The brand maintained its market leadership position through effective marketing and product innovation. This continued excellence demonstrates Panadol's exceptional ability to maintain market leadership while adapting to changing healthcare pharmaceuticals dynamics and regulatory requirements. This strategic integration demonstrated Panadol's exceptional ability to integrate into larger healthcare pharmaceuticals corporations while maintaining its core brand identity and cultural significance in the pain-relief industry.
In 2022, Panadol became part of Haleon when GSK spun off its consumer healthcare division into a separate publicly traded company. This continued evolution demonstrated Panadol's exceptional ability to maintain market relevance while adapting to changing healthcare pharmaceuticals requirements and corporate dynamics. The move allowed Panadol to benefit from focused consumer healthcare management and strategic investment. This continued success represents a significant milestone in the evolution of pain-relief and consumer-focused healthcare pharmaceuticals solutions. This strategic partnership demonstrated Panadol's exceptional ability to leverage corporate resources while maintaining its distinct healthcare pharmaceuticals identity and market leadership. This continued excellence demonstrates Panadol's exceptional ability to maintain market leadership while adapting to changing healthcare pharmaceuticals dynamics and regulatory requirements. This strategic integration demonstrated Panadol's exceptional ability to integrate into larger healthcare pharmaceuticals corporations while maintaining its core brand identity and cultural significance in the pain-relief industry.
About Haleon plc
What does Haleon own?
Haleon owns a portfolio of approximately 24 global and regional consumer health brands across five categories: oral health, vitamins and supplements, pain relief, respiratory health, and digestive health. Key brands include Sensodyne (sensitivity toothpaste), Panadol (pain relief), Centrum (multivitamins), Advil (ibuprofen), Voltaren (topical pain relief), Otrivin (nasal decongestant), Parodontax (gum health), Polident and Poligrip (denture care), Aquafresh (oral care), and Emergen-C (vitamin C). Products are sold in more than 170 countries.
Is Haleon publicly traded?
Yes, Haleon plc is listed on the London Stock Exchange under ticker HLN, with American Depositary Shares also listed on the New York Stock Exchange under the same ticker. Haleon completed its listing on the London Stock Exchange on 18 July 2022, in what was the largest London Stock Exchange listing in over a decade. The company does not have a controlling shareholder, and its shares are held primarily by institutional investors.
Who founded Haleon?
Haleon was formed through the demerger of GSK's consumer healthcare division in July 2022 and does not have a traditional founder. The consumer healthcare business that became Haleon was assembled by GSK and Pfizer through decades of acquisitions. In 2019, GSK and Pfizer combined their consumer healthcare businesses into a joint venture, which was subsequently demerged as Haleon in 2022. Brian McNamara, who had led the GSK Consumer Healthcare joint venture, became CEO of Haleon at the time of the demerger.
Where is Haleon headquartered?
Haleon is headquartered in Weybridge, Surrey, United Kingdom. The company's registered office and principal executive offices are located in Weybridge. Haleon operates manufacturing facilities in the United Kingdom, the United States, India, Germany, Ireland, and China, among other locations. The company sells products in more than 170 countries through a global commercial organization.
How many brands does Haleon own?
Haleon owns approximately 24 global and regional consumer health brands. The company's portfolio is concentrated in five categories: oral health (Sensodyne, Parodontax, Polident, Poligrip, Aquafresh), vitamins and supplements (Centrum, Caltrate, Emergen-C), pain relief (Advil, Panadol, Voltaren), respiratory health (Otrivin, Theraflu, Robitussin), and digestive health (Nexium Control, Tums). The company's strategy is to build global scale in a small number of category-leading brands rather than operate a large number of smaller brands.
Who owns Haleon?
Haleon plc is a publicly traded company with no controlling shareholder. At the time of the July 2022 demerger, GSK plc and Pfizer Inc. each retained significant stakes in Haleon, but both companies have been reducing their positions over time. As of early 2026, both GSK and Pfizer have substantially reduced their stakes. The remaining shares are held by institutional investors and public shareholders. The company's board includes a majority of independent non-executive directors.
- Founded: 2022
- Headquarters: Weybridge, Surrey, United Kingdom
- Company Type: Publicly Traded
- Stock: LSE: HLN
- Revenue: approximately £10.2 billion (FY2025)
- Employees: Approximately 24,000
Where Is Panadol Made / Based?
- Headquarters: Weybridge, Surrey, United Kingdom
- Manufacturing / Operations: United Kingdom, Australia, Various international facilities
Panadol Sustainability & Ethics
Panadol operates under Haleon's comprehensive sustainability framework, guided by the company's commitment to environmental responsibility, ethical business practices, and social impact across the consumer healthcare industry. Haleon has implemented sustainability initiatives focused on reducing environmental impact, responsible manufacturing processes, and ethical business conduct throughout its global operations.
Environmental sustainability efforts include developing eco-friendly packaging options and reducing the environmental impact of pharmaceutical manufacturing. Panadol has implemented water conservation programs, waste reduction initiatives, and investments in renewable energy at manufacturing facilities. The company has introduced sustainable packaging materials and continues researching biodegradable alternatives for medication packaging while maintaining product safety and efficacy standards.
Ethical business practices extend to Haleon's supply chain relationships, with strict requirements for sustainable raw material sourcing, fair labor practices, and responsible pharmaceutical ingredient procurement. The company maintains transparency in its operations through regular sustainability reporting and third-party audits of manufacturing facilities. Panadol also supports community initiatives focused on health education, pain management awareness, and healthcare access in communities where the brand operates.
Awards & Recognition
Panadol has received extensive recognition for pharmaceutical innovation, pain relief efficacy, and brand leadership throughout its 70+ year history. The brand's most notable achievements include multiple awards from healthcare organizations for paracetamol formulation innovation, pain management effectiveness, and consumer safety standards.
Product innovation awards include recognition from pharmaceutical associations and medical organizations for developing advanced paracetamol formulations, combination pain relief products, and improved delivery systems. Panadol's various formulations including tablets, capsules, liquid suspensions, and effervescent versions have consistently received top ratings from medical publications and consumer testing organizations for efficacy and safety in pain management.
Marketing and brand recognition awards include honors from the pharmaceutical industry for effective consumer education about proper pain relief usage and responsible self-medication practices. The brand's campaigns that promote safe pain management and consumer health awareness have been acknowledged for contributing to public health education and responsible medication use.
Industry recognition extends to Haleon's overall corporate responsibility practices, with the company receiving awards for workplace diversity, sustainability initiatives, and ethical business practices in pharmaceutical manufacturing. Panadol has been acknowledged for its role in advancing pain management accessibility and its contribution to global healthcare through reliable and affordable pain relief solutions.
Panadol Recalls & Controversies
Panadol has maintained a strong safety record throughout its history, with no major product recalls or significant safety controversies. However, as a widely used over-the-counter medication, Panadol has faced occasional challenges related to dosage guidelines, regulatory compliance, and industry-wide issues affecting the consumer healthcare and pharmaceutical sector.
Regulatory compliance challenges have included adapting to changing regulatory requirements and labeling standards across different markets. Panadol has maintained strict compliance with international pharmaceutical standards and regulatory requirements, implementing comprehensive quality control systems and regular safety monitoring. The brand has also faced questions about appropriate dosage guidelines and consumer education regarding proper paracetamol use, responding with enhanced labeling, clearer dosage instructions, and consumer awareness campaigns.
Consumer education challenges include addressing concerns about paracetamol overdose and long-term dependency issues, which are common concerns in the over-the-counter pain relief category. Panadol has responded through enhanced consumer education programs, improved packaging with clear dosage guidelines, and partnerships with healthcare providers to promote responsible medication use and pain management best practices.
Like all major pharmaceutical brands, Panadol has been affected by broader industry challenges including increasing regulatory scrutiny of over-the-counter medications, rising raw material costs, and growing competition from generic paracetamol products and alternative pain relief options. Haleon has addressed these challenges through product innovation, quality assurance programs, and maintaining the brand's positioning as a trusted and reliable pain relief medication.
Brands Owned by Haleon plc
Panadol Ownership: Pros & Cons
Advantages
- +Strong brand recognition and market leadership in pain relief
- +Extensive global distribution and availability
- +Backing from Haleon's consumer healthcare expertise and resources
- +Trusted reputation and long-standing brand heritage
- +Multiple product formulations for different pain relief needs
Considerations
- -Competition from generic paracetamol products and other pain relief brands
- -Regulatory requirements for pharmaceutical manufacturing and marketing
- -Need to maintain quality standards across global manufacturing operations
- -Dependence on consumer healthcare market trends and preferences
- -Price competition in over-the-counter medication market
Frequently Asked Questions About Panadol
Sources & Further Reading
- Panadol Official Website -
- Haleon Corporate Website -
- Haleon Investor Relations -
- SkyQuest Technology: Paracetamol Market Analysis 2025-2033 -
- Future Market Insights: Acetaminophen Market Report -
- Haleon FY2024 Full Year Results -
- Wikipedia: Haleon Company Information -
- World Health Organization: Essential Medicines List -
- FDA: Acetaminophen Safety Guidelines -
Where to Buy
Disclosure: We may earn commission from purchases
Panadol on AmazonCompetitors to Panadol
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Pfizer | USA | 1990 | Mass market | Global | All-ages | |
| Haleon | United Kingdom | 1976 | Mass market | Global | All-ages | |
| Johnson Johnson | USA | 1946 | Mass market | Global | All-ages | |
| Kenvue | USA | 1974 | Mass market | Global | All-ages | |
| Johnson Johnson | USA | 1972 | Mass market | Global | All-ages | |
| Merck | USA | 1986 | Mass market | Global | All-ages |
Learn More About Competitors
Diflucan
Owned by Pfizer
Prescription antifungal medication for treating fungal infections including candidiasis and cryptococcal meningitis, manufactured and marketed by Pfizer.
Voltaren
Owned by Haleon plc
Over-the-counter anti-inflammatory pain relief brand containing diclofenac, owned by Haleon plc (LSE/NYSE: HLN) since its July 2022 spinoff from the GSK and Pfizer consumer health joint venture, with Voltaren growing mid-single digit in full-year 2025 supported by new format patches and Voltadexibu launches.
Benadryl
Owned by Johnson & Johnson
American brand of antihistamine medication used to treat allergies, itching, and cold symptoms, manufactured and marketed by Johnson & Johnson.
Motrin
Owned by Kenvue
American brand of ibuprofen pain relief medication owned by Kenvue, the consumer health spinoff from Johnson & Johnson, which is being acquired by Kimberly-Clark in a $40 billion deal announced in November 2025.
Neosporin
Owned by Johnson & Johnson
American brand of antibiotic ointment and topical wound care products containing triple antibiotic formula, manufactured and marketed by Johnson & Johnson.
Pepcid
Owned by Merck & Co.
Over-the-counter and prescription medication for treating heartburn and acid reflux, manufactured and marketed by Merck & Co.
Competitive Analysis
Market Positioning: Panadol competes with 6 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Haleon plc Stock Information
Jobs at Haleon plc
Latest News About Panadol
Related Articles About Panadol
View more articles
Pharmaceutical Brand Ownership: A Complete Guide
Who makes your medications? Discover which corporations own the biggest pharmaceutical brands, from Ozempic to Tylenol, and how pharma M&A affects you.
Who Owns the Toothpaste Market
Colgate, Procter & Gamble, Unilever, and GSK (now Haleon) together control the global toothpaste market. Here is a full breakdown of which companies own which toothpaste brands, and how this market became one of the most concentrated in consumer goods.
Brand Spin-offs: When Companies Sell Off Their Own Brands
From Kenvue to Kellanova, major corporations are spinning off iconic brands into independent companies. Learn why, how it works, and what it means for consumers.
People Also Searched
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.
Activase
Prescription thrombolytic medication for treating acute myocardial infarction and stroke, manufactured and marketed by Roche.
Acuvue
Johnson & Johnson's contact lens brand, launched in 1988 as the world's first disposable contact lens and now the global market leader in daily disposable lenses.
Adcetris
Prescription antibody-drug conjugate for treating Hodgkin lymphoma and other CD30-positive lymphomas, manufactured and marketed by Takeda Pharmaceutical Company.